Astrid Weyerbrock

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp, Monika E. Hegi, Thierry Gorlia et al. · The Lancet Oncology · 2014 · 1K citations

Medicine, Oncology, Pharmacotherapy +14

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 576 citations · Full text

Medicine, Oncology, Pharmacology +16

Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection

Florian Ringel, Haiko Pape, Michael Sabel et al. · Neuro-Oncology · 2015 · 263 citations · Full text

Medicine, Oncology, Surgery +17

Transcriptome analysis reveals tumor microenvironment changes in glioblastoma

Youri Hoogstrate, Kaspar Draaisma, Santoesha A. Ghisai et al. · Cancer Cell · 2023 · 249 citations · Full text

Medicine, Cancer Biology, Oncology +17

<i>NFKBIA</i> Deletion in Glioblastomas

Markus Bredel, Denise Scholtens, Ajay K. Yadav et al. · New England Journal of Medicine · 2010 · 243 citations · Full text

Medicine, Cancer Biology, Molecular Biology +17